China SXT Pharmaceuticals, Inc. (SXTC)
NASDAQ: SXTC · IEX Real-Time Price · USD
1.050
+0.020 (1.94%)
At close: Apr 26, 2024, 4:00 PM
1.030
-0.020 (-1.90%)
After-hours: Apr 26, 2024, 7:59 PM EDT
China SXT Pharmaceuticals Revenue
China SXT Pharmaceuticals had revenue of $29.92K in the twelve months ending September 30, 2023. In the fiscal year ending March 31, 2023, China SXT Pharmaceuticals had annual revenue of $33.62K, a decrease of -90.09%.
Revenue (ttm)
$29.92K
Revenue Growth
-90.09%
P/S Ratio
366.61
Revenue / Employee
$384
Employees
78
Market Cap
10.97M USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2023 | 33.62K | -305.51K | -90.09% |
| Mar 31, 2022 | 339.13K | -545.86K | -61.68% |
| Mar 31, 2021 | 884.99K | 554.56K | 167.83% |
| Mar 31, 2020 | 330.43K | 118.28K | 55.75% |
| Mar 31, 2019 | 212.16K | -1.10M | -83.89% |
| Mar 31, 2018 | 1.32M | 585.53K | 80.04% |
| Mar 31, 2017 | 731.51K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| iCoreConnect | 8.15M |
| Biomerica | 5.41M |
| Elevai Labs | 1.71M |
| Can-Fite BioPharma | 743.00K |
| Inhibikase Therapeutics | 260.50K |
| Nexalin Technology | 110.75K |
| Bionomics | 15.00K |
SXTC News
- 6 months ago - China SXT Pharmaceuticals, Inc. Regained Compliance with Nasdaq's Minimum Bid Price Rule - GlobeNewsWire
- 7 months ago - China SXT Pharmaceuticals Announces One-for-Twenty-five Reverse Stock Split - GlobeNewsWire
- 2 years ago - China SXT Pharmaceuticals, Inc. Announces 1 for 20 Reverse Share Split - GlobeNewsWire
- 2 years ago - China SXT Pharmaceuticals, Inc. Enters into Securities Purchase Agreement to Issue a 6% Convertible Promissory Note in the Original Principal Amount of $2.8 Million - GlobeNewsWire
- 2 years ago - Aegis Capital Corp. Acted as Sole Bookrunner on a $4.1 Million Underwritten Public Offering of Ordinary Shares, Inclusive of the Over-Allotment, for China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC). - Accesswire
- 2 years ago - China SXT Pharmaceuticals, Inc. Announces Successful Closing of $4.1 Million Follow-on Underwritten Offering of Ordinary Shares and Pre-Funded Warrants With Simultaneous Exercise of the Over-Allotment - GlobeNewsWire
- 2 years ago - China SXT Pharmaceuticals, Inc. Prices $3.5 Million Underwritten Public Offering of Ordinary Shares and Pre-Funded Warrants to Purchase Ordinary Shares - GlobeNewsWire
- 2 years ago - China SXT Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Ordinary Shares and Pre-Funded Warrants to Purchase Ordinary Shares - GlobeNewsWire